Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SciPhage is a Colombian biotechnology company specializing in the development of bacteriophage-based solutions to address the global crisis of antimicrobial resistance. Founded in 2014 as a spin-off from the Universidad de los Andes, the company focuses on creating organic bioproducts for animal health, human health, and aquaculture. Its flagship product, SalmoFree, is a phage cocktail designed to control Salmonella in poultry, which has demonstrated significant efficacy in large-scale field trials involving over 550,000 birds. SciPhage operates the first dedicated bacteriophage production plant in Colombia and is expanding its pipeline to include treatments for acne and aquaculture-related infections. The company's business-to-business model aims to improve food safety and agricultural productivity while reducing reliance on traditional antibiotics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SciPhage.